Emergence

Global Smart Agriculture Market to Reach $25.4 Billion by 2028, Fueled by Increasing Global Population and Adoption of Modern Technologies

Retrieved on: 
Tuesday, July 25, 2023
Farm, Pressure, Prevalence, Education, Internet of things, Farmer, Agriculture, Aquaculture, Livestock, Emergence, Unmanned aerial vehicle, USD, Row, Market, Water, Hardware, Growth, Project delivery method, Environment, Director General of the European Union Military Staff, Rare-earth element, Software

The global smart agriculture market is poised for significant growth, projected to reach USD 25.4 billion by 2028, with a CAGR of 9.4% from 2023 to 2028, as per latest estimates.

Key Points: 
  • The global smart agriculture market is poised for significant growth, projected to reach USD 25.4 billion by 2028, with a CAGR of 9.4% from 2023 to 2028, as per latest estimates.
  • The market growth is driven by factors such as the increasing global population, which exerts pressure on the food supply system, and the shortage of skilled labor in the agriculture industry.
  • The precision farming segment is expected to lead the smart agriculture market during the forecast period, fueled by the rapid adoption of state-of-the-art technologies and innovative devices to cultivate high-yield crops.
  • Geographically, the Americas held the largest share of the overall smart agriculture market in 2022, followed by Europe, Asia-Pacific, and the Rest of the World (RoW).

EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Retrieved on: 
Thursday, July 13, 2023
State University of New York, AACR, EAP, GCC, Half-life, HPHA, ATAC, SRC, Binghamton University, Multiple myeloma, Clinical trial, State university system, Bone marrow, Cancer, American Association for Cancer Research, FSE, Magenta, Research, ATACS, Sale, Spanish mythology, Amanitin, Data analysis, CAIX, Patient, Antibody-drug conjugate, Microsoft Access, Marketing, CFO, Management, Ethics, ADC, Eli Lilly and Company, Depreciation, Spacecraft, Phase, FDA, Therapy, Market Access Program, Safety, Disease, Pharmaceutical industry, Vaccine, Fine chemical, Generic drug, Cryptocurrency, Telix, Emergence

Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).

Key Points: 
  • Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).
  • HDP-101 (BCMA-ATAC) program: Heidelberg Pharma presented preliminary safety data from the clinical trial with HDP-101.
  • The Heidelberg Pharma Group (Heidelberg Pharma) – comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The full-year financial guidance issued on 24 March 2023 for the Heidelberg Pharma Group is confirmed at this time.

Global Causal AI Market Forecast Report to 2030: Potential to Revolutionize Healthcare Field

Retrieved on: 
Monday, June 26, 2023
IBM, Cognizant, Importance, Microsoft, Research, Emergence, Privacy, USD, Causal inference, Pulse, Organization, Explainable artificial intelligence, Investment, Drug discovery, Growth, Region, Ethics, AWS, Dynatrace, Software, Medical device, Causality, Causal AI, AI

DUBLIN, June 26, 2023 /PRNewswire/ -- The "Global Causal AI Market by Offering, Vertical and Region - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 26, 2023 /PRNewswire/ -- The "Global Causal AI Market by Offering, Vertical and Region - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Causal AI and Causal ML is used in healthcare and life sciences for drug discovery, patient diagnosis, treatment, personalized medicine, and more.
  • The report provides insights on the following:
    Analysis of key drivers (Importance of Causal Inference Models in Various Fields, Emergence of Causal AI as a Solution to Overcome the Limitations of Current AI, Operationalizing AI initiatives), restraints (Lack of interpretability & explainability and Acquiring & preparing high-quality data), opportunities (Causal AI is its potential to revolutionize the field of healthcare and Technological advancements in Causal AI), and challenges (Causal Inference from Complex Data Sets, Lack of Standardization and Ethical and Legal Issues) influencing the growth of the Causal AI market
    Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the Causal AI market.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in Causal AI and Causal ML market strategies; the report also helps stakeholders understand the pulse of the Causal AI market and provides them with information on key market drivers, restraints, challenges, and opportunities
    Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players such as IBM, Google , AWS, Microsoft, Cognizant and Dynatrace among others in the Causal AI market.

Interactive Robots Global Market Report 2023: Robotics-As-A-Service (RaaS) Garners Attention for all the Right Reasons

Retrieved on: 
Wednesday, May 31, 2023
Natural language processing, Way, Conversational commerce, ChatGPT, Emergence, NLP, Marketing, Development, Affective computing, Natural language, Robotics

Growing Spending on Conversational Commerce Opens a Parallel Opportunity for Chatbots in Marketing & Customer Care Operations: Global Market for Conversational Commerce (In US$ Billion) for Years 2023, 2025, 2027, 2029 and 2031

Key Points: 
  • Growing Spending on Conversational Commerce Opens a Parallel Opportunity for Chatbots in Marketing & Customer Care Operations: Global Market for Conversational Commerce (In US$ Billion) for Years 2023, 2025, 2027, 2029 and 2031
    Affective Computing Paves the Way for the Development of More Interactive, Responsive, Human Like Robots
    Advances in Affective Computing Make Emotion Recognition for Human-Robot Interaction a Reality: Global Market for Affective Computing (In US$ Billion) for Years 2023, 2025, 2027, 2029 and 2031
    Demand for More Intuitive & Interactive Solutions Paves the Way for the Emergence of Robotics as an Important Area of Application for Gesture Recognition: Global Market for Gesture Recognition (In US$ Million) for Years 2023, 2025 and 2027
    ChatGPT Ushers a New Beginning in the Era in Robotics, Beginning With Easy Interactivity
    Continuous Advancements in NLP Remains Crucial for Building Seamless Interactive Skills of Robots: Global Market for Natural Language Processing (NLP) in US$ Billion for Years 2023, 2025, 2027 and 2029

Irwin Naturals Reports Year End 2022 Financial Results and Recent Events

Retrieved on: 
Thursday, May 25, 2023
Serenity, Bismuth, CSE, FRA, Acquisition, Investment, OTC, Ketamine, CFO, Cannabis, Growth, THC, Drug, Pharmaceutical industry, Emergence

LOS ANGELES, May 25, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2022, on www.sedar.com.

Key Points: 
  • LOS ANGELES, May 25, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2022, on www.sedar.com.
  • Income from operations decreased $8.7 million from $10.6 million in 2021 to $1.8 million in 2022.
  • The decrease is primarily attributed to an overall decrease in business volume from 2021 paired with startup costs related to the Company’s 2022 Acquisitions at Irwin Naturals Emergence (the company acquired twelve mental health clinics in 2022) and Irwin Naturals Cannabis (intellectual property licensing to the cannabis industry).
  • Announced a licensing agreement with a partner in Oklahoma to produce and distribute Irwin Naturals THC products.

New Research Shows Automakers Face Consumer Skepticism Toward Vehicle Feature Subscriptions

Retrieved on: 
Monday, May 15, 2023
Desire, Smartphone, Research, Emergence, Privacy, Cox Enterprises, Knowledge, Automotive industry, FOD, Safety, Online shopping, Pharmaceutical industry, Car dealership, Television, Mobile phone, Retail

ATLANTA, May 15, 2023 /PRNewswire/ -- According to consumer research from Cox Automotive, automakers may face challenges if they expect to generate significant revenue from subscription-type features, also known as Features on Demand (FoD).

Key Points: 
  • ATLANTA, May 15, 2023 /PRNewswire/ -- According to consumer research from Cox Automotive, automakers may face challenges if they expect to generate significant revenue from subscription-type features, also known as Features on Demand (FoD).
  • Research shows Automakers may face challenges in making significant revenue from subscription-based vehicle features.
  • In a new study titled "Software Monetization: The Emergence of Vehicle Features on Demand," the Cox Automotive Research and Market Intelligence team explores the trend toward offering vehicle features through subscription-type services.
  • To gain consumer acceptance, automakers must ensure consumers perceive subscription-based features as a good value and not just a money-grab."

Empowers Africa & Off Piste Africa Partner with Streaming Platform, WaterBear, to Launch "Emergence", a Documentary on Super Tuskers

Retrieved on: 
Tuesday, May 9, 2023
Film & Motion Pictures, Technology, Philanthropy, Online, General Entertainment, Entertainment, Other Philanthropy, Apps, Applications, Software, Internet, Foundation, AirPlay, Human, FAST, Tsavo Trust, Samsung, Emergence, Elephant, Non-governmental organization, Trustee, Tardigrade, Ecosystem, Habitat, Environment, Empowerment, Film industry, Television

The documentary, produced by Malcolm Randles, Off Piste Africa and Empowers Africa, sheds light on the urgent need to protect Tsavo's super tuskers, rare elephants with unique genetic dispositions that are under severe threat.

Key Points: 
  • The documentary, produced by Malcolm Randles, Off Piste Africa and Empowers Africa, sheds light on the urgent need to protect Tsavo's super tuskers, rare elephants with unique genetic dispositions that are under severe threat.
  • Tsavo Trust's Big Tusker Project is dedicated to preserving these majestic beasts and their habitat in Tsavo, Kenya.
  • "Thank you to WaterBear for launching this film on their platform and showing the world why we need to protect Tsavo's super tuskers."
  • Poppy Mason-Watts, Chief Growth & Impact Officer at WaterBear says, "We are thrilled to partner with Empowers Africa to release 'Emergence' on WaterBear.

Irwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical Companies in the US

Retrieved on: 
Tuesday, January 10, 2023
Invictus, OTC, LOI, Mental health, Depression, CSE, Government, FRA, FDA, Partnership, Psychiatry, Patient, Letter, Science, Pharmaceutical industry, Emergence

The partnership will bring together Braxia’s expertise, track record of leadership in innovative mental health treatments and current comprehensive clinical research capabilities to 12 Emergence clinics in 5 US states.

Key Points: 
  • The partnership will bring together Braxia’s expertise, track record of leadership in innovative mental health treatments and current comprehensive clinical research capabilities to 12 Emergence clinics in 5 US states.
  • Under the terms of the LOI, Irwin will invest up to $2 million over the next 12 months to launch initial clinical research services beginning with at least 5 clinics in Florida.
  • Irwin and Braxia’s partnership will create a leading mental health focused clinical research platform designed to streamline and accelerate the process of in-human clinical development of new therapies, including seamless patient recruitment through to FDA application.
  • Having an outstanding reputation for scientific expertise, quality clinical research in depression and other mental health disorders areas that will enable us to further develop our US clinical footprint."

Another Award for Synaffix: 'Business Development Team of Year' at the Scrip Awards

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Therapy, Trust, LSX, Business, Therapeutic index, BD, Aravis, Conference, Emergence, Patient, Cancer, ADC, Disease, Kyowa Hakko Kirin, Moa, Royal Lancaster Infirmary, Control, Royal, Business development, Fine chemical, Pharmaceutical industry, Synaffix

The Scrip Award recognizes the successful track record of Synaffix's Business Development (BD) team in delivering high-value deals and world-class science in the highly sought-after ADC space.

Key Points: 
  • The Scrip Award recognizes the successful track record of Synaffix's Business Development (BD) team in delivering high-value deals and world-class science in the highly sought-after ADC space.
  • The BD Team has been instrumental in the signing of six licensing deals during the award qualifying period with deal values around $500 million to $1 billion.
  • These include agreements with Mersana ($1b), Genmab ($415m), Macrogenics ($586m), Kyowa Kirin (value not disclosed) and Emergence Therapeutics ($360m).
  • toxSYN is a linker-payload platform that spans key, validated MOAs for ADC product development, including SYNtecan E and SYNeamicin G, among other linker-payloads.

Another Award for Synaffix: 'Business Development Team of Year' at the Scrip Awards

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Therapy, Trust, LSX, Business, Therapeutic index, BD, Aravis, Conference, Emergence, Patient, Cancer, ADC, Disease, Kyowa Hakko Kirin, Moa, Royal Lancaster Infirmary, Control, Royal, Business development, Fine chemical, Pharmaceutical industry, Synaffix

The Scrip Award recognizes the successful track record of Synaffix's Business Development (BD) team in delivering high-value deals and world-class science in the highly sought-after ADC space.

Key Points: 
  • The Scrip Award recognizes the successful track record of Synaffix's Business Development (BD) team in delivering high-value deals and world-class science in the highly sought-after ADC space.
  • The BD Team has been instrumental in the signing of six licensing deals during the award qualifying period with deal values around $500 million to $1 billion.
  • These include agreements with Mersana ($1b), Genmab ($415m), Macrogenics ($586m), Kyowa Kirin (value not disclosed) and Emergence Therapeutics ($360m).
  • toxSYN is a linker-payload platform that spans key, validated MOAs for ADC product development, including SYNtecan E and SYNeamicin G, among other linker-payloads.